Table 4 Adjusted sub-distribution hazard ratios for developing atrial fibrillation by cancer treatment type among breast cancer surgery survivors by age categories

Anthracyclines

 No

9/4532

0.38

1 (Ref.)

59/18,346

0.62

1 (Ref.)

195/21,802

1.75

1 (Ref.)

328/9843

7.07

1 (Ref.)

 Yes

42/7733

1.02

3.07 (1.47–6.42)

112 /22,141

0.95

1.69 (1.18–2.40)

302/25,332

2.33

1.53 (1.20–1.93)

119/3503

7.10

1.51 (1.15–1.98)

Taxane

 No

15/4426

0.64

1 (Ref.)

56/16,694

0.65

1 (Ref.)

170/18,796

1.77

1 (Ref.)

289/8176

7.47

1 (Ref.)

 Yes

36/7839

0.86

0.92 (0.49–1.71)

115/23,793

0.92

0.93 (0.65–1.33)

327/28,338

2.26

0.85 (0.67–1.09)

158/5170

6.45

0.81 (0.63–1.03)

Trastuzumab

 No

44/10,465

0.78

1 (Ref.)

142/35,100

0.77

1 (Ref.)

410/38,765

2.05

1 (Ref.)

400/11,957

7.02

1 (Ref.)

 Yes

7/1800

0.78

0.85 (0.38–1.89)

29/5387

1.08

1.16 (0.78–1.74)

87/8369

2.12

0.88 (0.69–1.12)

47/1389

7.57

1.05 (0.77–1.44)

Endocrine therapy

 No

24/4462

1.04

1 (Ref.)

53/10,629

0.99

1 (Ref.)

168/15,998

2.10

1 (Ref.)

141/4218

7.34

1 (Ref.)

 Tamoxifen

27/7741

0.65

0.59 (0.34–1.02)

106/28,566

0.70

0.72 (0.52–1.00)

91/11,024

1.57

0.94 (0.72–1.21)

70/2243

6.32

0.82 (0.61–1.09)

 AIs

0/35

0

NA

8/1149

1.27

1.01 (0.48–2.13)

233/19,253

2.37

1.04 (0.85–1.27)

230/6609

7.30

1.03 (0.84–1.27)

 Both

0/27

0

NA

4/143

5.15

NA

5/859

1.12

NA

6/276

4.40

0.57 (0.25–1.28)

Radiation therapy

 No

12/3485

0.67

1 (Ref.)

42/11,160

0.73

1 (Ref.)

144/13,091

2.17

1 (Ref.)

235/6420

7.81

1 (Ref.)

 Yes

39/8780

0.83

1.18 (0.62–2.25)

129/29,327

0.83

1.11 (0.79–1.58)

353/34,043

2.02

0.96 (0.79–1.17)

212/6926

6.41

0.99 (0.82–1.20)